Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Inclusion Criteria:

• diagnosis of spontaneous SAH
• impaired cerebral autoregulation on day 2-4 post SAH

Exclusion Criteria:

• traumatic SAH
• other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations
• pregnancy
• severe renal disease or anuria